Callan Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Callan Capital’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-158,500	Closed	-$33.4K	–	212
2023 Q2	$33.4K	Hold	158,500	–	–	﹤0.01%	180
2023 Q1	$25.4K	Hold	158,500	–	–	﹤0.01%	180
2022 Q4	$88K	Buy	+158,500	New	+$135K	0.01%	181
2022 Q1	–	Sell	-146,200	Closed	-$329K	–	140
2021 Q4	$329K	Hold	146,200	–	–	0.05%	96
2021 Q3	$500K	Buy	146,200 +24,400	+20%	+$75.2K	0.08%	66
2021 Q2	$364K	Buy	+121,800	New	+$385K	0.06%	72
2021 Q1	–	Sell	-73,200	Closed	-$155K	–	88
2020 Q4	$155K	Buy	+73,200	New	+$121K	0.03%	80

Other funds holding INFI

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Callan Capital's INFI Position: Q3 2023 in Review

Callan Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 158,500 shares — an estimated $33.4K sold.

Callan Capital first reported a position in INFI in Q4 2020 and held it in 7 quarters. The position peaked at $500K in Q3 2021. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

Callan Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Callan Capital sold 158,500 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $33.4K.
Callan Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2020 and held it in 7 quarters.
Callan Capital's Infinity Pharmaceuticals, Inc. position peaked at $500K in Q3 2021.
3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on Callan Capital's 13F filing for Q3 2023, filed 6 Nov 2023.